FR2541115B1 - Medicament renfermant un peptide en tant que principe actif pour le traitement des affections ulcereuses - Google Patents

Medicament renfermant un peptide en tant que principe actif pour le traitement des affections ulcereuses

Info

Publication number
FR2541115B1
FR2541115B1 FR8320945A FR8320945A FR2541115B1 FR 2541115 B1 FR2541115 B1 FR 2541115B1 FR 8320945 A FR8320945 A FR 8320945A FR 8320945 A FR8320945 A FR 8320945A FR 2541115 B1 FR2541115 B1 FR 2541115B1
Authority
FR
France
Prior art keywords
treatment
active ingredient
containing peptide
medicament containing
ulcerous conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8320945A
Other languages
English (en)
Other versions
FR2541115A1 (fr
Inventor
V N Smirnov
M I Titov
Z D Bespalova
A A Azmuko
T R Sax
O S Medvedev
N I Rozhanskaya
V G Smagin
V A Vinogradov
V M Polonsky
S A Bulgakov
V N Ivanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VSESOJUZNYJ KARDIOLOGITSCHES
Original Assignee
VSESOJUZNYJ KARDIOLOGITSCHES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VSESOJUZNYJ KARDIOLOGITSCHES filed Critical VSESOJUZNYJ KARDIOLOGITSCHES
Publication of FR2541115A1 publication Critical patent/FR2541115A1/fr
Application granted granted Critical
Publication of FR2541115B1 publication Critical patent/FR2541115B1/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR8320945A 1982-12-29 1983-12-28 Medicament renfermant un peptide en tant que principe actif pour le traitement des affections ulcereuses Expired FR2541115B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU823569889A SU1414392A1 (ru) 1982-12-29 1982-12-29 Противо звенное средство

Publications (2)

Publication Number Publication Date
FR2541115A1 FR2541115A1 (fr) 1984-08-24
FR2541115B1 true FR2541115B1 (fr) 1988-12-23

Family

ID=21055718

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8320945A Expired FR2541115B1 (fr) 1982-12-29 1983-12-28 Medicament renfermant un peptide en tant que principe actif pour le traitement des affections ulcereuses

Country Status (10)

Country Link
US (1) US4565805A (fr)
JP (1) JPS60500174A (fr)
BE (1) BE898559A (fr)
CH (1) CH661869A5 (fr)
DE (1) DE3390419C2 (fr)
FR (1) FR2541115B1 (fr)
GB (1) GB2141627B (fr)
IT (1) IT1212909B (fr)
SU (1) SU1414392A1 (fr)
WO (1) WO1984002470A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1348343A1 (ru) * 1984-07-16 1987-10-30 Всесоюзный кардиологический научный центр АМН СССР Гексапептид,обладающий антипанкреонекротической активностью
SU1460965A1 (ru) * 1987-06-19 1991-10-15 Всесоюзный кардиологический научный центр АМН СССР Гексапептид, обладающий противо звенным действием
JPH02501389A (ja) * 1987-10-02 1990-05-17 フセソユズニ　カルディオロジチェスキ　ナウチニ　ツェントル　アカデミイ　メディツィンスキフ　ナウク　エスエスエスエル 多発性硬化症及び筋萎縮側索硬化症の治療用薬用製剤
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
ES2063912T3 (es) * 1989-01-24 1995-01-16 Aphton Corp Composiciones inmunogenicas frente a peptidos de gastrina.
US6861510B1 (en) 1989-01-24 2005-03-01 Aphton Corporation Immunogenic compositions against gastrin peptides
US20040001842A1 (en) * 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
EP0981369B1 (fr) * 1997-05-12 2004-11-17 Aphton Corporation Compositions immunogenes dirigees contre le recepteur de cck-b/gastrine et procede de traitement des tumeurs
DK1077721T3 (da) * 1998-05-15 2007-09-03 Receptor Biologix Inc Forebyggelse og behandling af hypergastrinæmi
US20030068326A1 (en) * 1998-05-15 2003-04-10 Aphton Corporation Method for the treatment of gastroesophageal reflux disease
WO2002076499A2 (fr) * 2001-03-23 2002-10-03 Aphton Corporation Traitement combine du cancer du pancreas
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
KR20040049830A (ko) * 2001-07-09 2004-06-12 애프톤 코포레이션 간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방
US6810583B2 (en) * 2001-08-07 2004-11-02 International Business Machines Corporation Coupling of conductive vias to complex power-signal substructures
US20060020119A1 (en) * 2004-03-29 2006-01-26 Stephen Grimes Monoclonal antibodies to gastrin hormone
CN1781023A (zh) * 2003-03-28 2006-05-31 埃弗顿有限公司 胃泌素激素免疫测定
WO2006032980A1 (fr) * 2004-09-22 2006-03-30 Receptor Biologix, Inc. Anticorps monoclonaux de progastrine
US11583576B2 (en) 2017-06-15 2023-02-21 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
WO2020027686A1 (fr) * 2018-08-03 2020-02-06 Сергей Георгиевич МОРОЗОВ Méthode de prophylaxie de l'insuffisance d'anastomose interintestinale

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU892871A1 (ru) * 1980-07-28 1983-09-15 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср Циклический аналог брадикинина,обладающий пролонгированным гипотензивным действием

Also Published As

Publication number Publication date
US4565805A (en) 1986-01-21
GB2141627B (en) 1985-12-18
WO1984002470A1 (fr) 1984-07-05
GB8418367D0 (en) 1984-08-22
GB2141627A (en) 1985-01-03
IT8349596A0 (it) 1983-12-28
DE3390419T1 (de) 1985-01-24
IT1212909B (it) 1989-11-30
CH661869A5 (de) 1987-08-31
BE898559A (fr) 1984-06-27
JPS60500174A (ja) 1985-02-07
SU1414392A1 (ru) 1988-08-07
DE3390419C2 (de) 1987-11-05
FR2541115A1 (fr) 1984-08-24

Similar Documents

Publication Publication Date Title
FR2541115B1 (fr) Medicament renfermant un peptide en tant que principe actif pour le traitement des affections ulcereuses
IT8024369A0 (it) Preparazione contenente metilsolfonilmetano e procedimenti per l'impiego e la purificazione di essa.
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
FR2430410A1 (fr) Phenethanolamines et compositions pharmaceutiques en contenant
FI831998A0 (fi) Foerfarande foer framstaellning av farmaceutiskt aktiva pyrazinonderivat
NO833279L (no) Farmasoeytiske preparater for behandling av uoensket sammenvoksing
FI854926A0 (fi) Foerfarande foer framstaellning av farmakologiskt aktiva pyrrolobensimidazoler.
BE885291A (fr) Compositions pharmaceutiques pour le traitement des dysfonctionnements cardiaques
BE871753A (fr) Nouvelle utilisation therapeutique de l'acetyl-1-carnitine pour le traitement des affections cardiaques
RO88351A3 (fr) Composition pour le traitement des affections gastroduodenales
IT1159815B (it) Composizione medicinale per il trattamento di certe neurovirosi
FR2515961B1 (fr) Preparations medicamenteuses contenant un derive d'acide tetraiodothyrocarboxylique notamment pour le traitement de l'hypercholesterolemie
PT87079A (pt) Process for the preparation of dopamine-beta-hydroxylase inhibitors and of pharmaceutical compounds containing them
RO79428A2 (fr) Composition medicamenteuse pour le traitement des dermatoses
BE837294A (fr) Preparations pharmaceutiques pour le traitement des troubles de la circulation
FR2521006B1 (fr) Nouveau medicament compose utile notamment pour le traitement des maladies infectieuses
BE892339A (fr) Agents pour le traitement d'affections cardiaques coronariennes
BE892781A (fr) Nouvelles compositions pharmaceutiques pour le traitement du diabete
RO69900A2 (fr) Solution medicamenteuse pour le traitement des affections de la muqueuse nasale
RO84903A2 (fr) Solution medicamenteuse pour le traitement des affections otiques
RO76760A2 (fr) Medicament destine au traitement des affections biliaires
RO88712A2 (fr) Medicament pour le traitement des piodermites
RO76759A2 (fr) Medicament destine au traitement des affections hepatiques
RO75580A2 (fr) Comprimes pour le traitement des affections bucco-pharingiene
RO77124A2 (fr) Composition medicamenteuse destinee au traitement des aphtes buccals

Legal Events

Date Code Title Description
ST Notification of lapse